Repligen | RGEN - Current Assets


Repligen reported $1.24B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Agilent USD 4.69B 70M Jun/2026
Align Technology USD 2.73B 63.03M Sep/2026
Bio Techne USD 824.83M 80.43M Sep/2026
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Bruker USD 2.16B 67.9M Sep/2026
Charles River Laboratories USD 1.54B 5.92M Sep/2026
Danaher USD 14.79B 1.41B Sep/2026
Dentsply International USD 1.98B 50M Sep/2026
General Electric Aerospace USD 41.53B 1.83B Sep/2026
Henry Schein USD 4.78B 176M Sep/2026
Illumina USD 3.04B 201M Sep/2026
IQVIA Holdings USD 6.45B 225M Sep/2026
Mettler Toledo International USD 1.38B 28.79M Sep/2026
Myriad Genetics USD 289M 23.8M Jun/2026
OraSure Technologies USD 222.94M 17.84M Jun/2026
Pacific Biosciences Of California USD 307.85M 30.78M Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Repligen USD 1.24B 41.43M Sep/2026
Revvity USD 1.86B 436.33M Sep/2026
Standard Biotools USD 497.3M 19.56M Sep/2026
Thermo Fisher Scientific USD 25.62B 2.25B Sep/2026
Waters USD 3.9B 186M Jun/2026
West Pharmaceutical Services USD 1.82B 9M Sep/2026